{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:51:44Z","timestamp":1779216704968,"version":"3.51.4"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/01.jaa.0000443810.42907.ec","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T10:21:29Z","timestamp":1393323689000},"page":"14-17","source":"Crossref","is-referenced-by-count":3,"title":["What are extended-spectrum beta-lactamases?"],"prefix":"10.1097","volume":"27","author":[{"given":"S. Scott","family":"Sutton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"4","key":"R1-3-20210130","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"R2-3-20210130","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum beta-lactamases: a clinical update.","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"R3-3-20210130","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"R4-3-20210130","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/JCM.42.3.1089-1094.2004","article-title":"Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase producing Escherichia coli in nonhospitalized patients.","volume":"42","author":"Rodriguez-Bano","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"1","key":"R6-3-20210130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":". Antibiotic therapy for Klebsiella pneumonia bacteremia: implications of production of extended-spectrum beta-lactamases.","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"6","key":"R7-3-20210130","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microbiol"},{"issue":"4","key":"R8-3-20210130","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R9-3-20210130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1469-0691.2005.01290.x","article-title":"High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.","volume":"12","author":"Goethaert","year":"2006","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"R10-3-20210130","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumonia and Escherichia coli.","volume":"56","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"R11-3-20210130","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00381-05","article-title":". Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.","volume":"50","author":"Gavin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"R12-3-20210130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"-Lactam-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum -lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.","volume":"54","author":"Rodriguez-Bano","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"9","key":"R13-3-20210130","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/AAC.00218-06","article-title":"Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumonia: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.","volume":"50","author":"Zimhony","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"R14-3-20210130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"R15-3-20210130","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/jac\/dkl414","article-title":"Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England.","volume":"58","author":"Hope","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"R16-3-20210130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1086\/518710","article-title":"In vitro activity of colistin against multidrug-resistant gram-negative bacteria isolated at a major army hospital during the military campaigns in Iraq and Afghanistan.","volume":"45","author":"Paolino","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"2","key":"R17-3-20210130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/380645","article-title":"Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin.","volume":"38","author":"Endimiani","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["Journal of the American Academy of Physician Assistants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000443810.42907.ec","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T18:40:42Z","timestamp":1620931242000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01720610-201403000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000443810.42907.ec","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}